Biotechnology company Ionis Pharmaceuticals Inc (Nasdaq:IONS) announced on Tuesday that it has entered into an expanded licensing agreement with Japan's Otsuka Pharmaceutical Co Ltd for donidalorsen, an investigational RNA-targeted therapy for hereditary angioedema (HAE).
Otsuka gains exclusive commercialisation rights in the Asia-Pacific region, adding to its commercialisation rights in Europe. Ionis retains responsibility for global development and plans a US Food and Drug Administration (FDA) filing this year for independent launch in the United States.
The agreement includes a USD20m upfront payment to Ionis with potential milestone and royalty payments tied to regulatory and sales achievements.
Otsuka's regional expertise and infrastructure aim to deliver donidalorsen to HAE patients across Asia-Pacific.
Lundbeck receives FDA Fast Track designation for amlenetug in multiple system atrophy
Moleculin's Phase 3 R/R AML pivotal trial receives first European country recruitment approval
Biohaven secures FDA priority review for troriluzole in spinocerebellar ataxia
Owens & Minor launches ByramConnect digital health platform for diabetes management
Novartis to acquire Anthos Therapeutics in USD925m deal to expand cardiovascular pipeline
bioMérieux secures US FDA clearance for new gastrointestinal diagnostic panel
EssilorLuxottica expands med-tech portfolio with Cellview acquisition
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Hemab Therapeutics reveals interim data from ongoing HMB-001 phase two study
AbbVie's EMBLAVEO receives US FDA approval for complicated intra-abdominal infections
Eton Pharmaceuticals secures US patent for ET-600, protecting formulation through 2044
Lilly's Omvoh shows sustained efficacy in Crohn's disease after two years
Bio-Thera Solutions secures EMA acceptance for BAT2506 biosimilar application
BioArctic reports strong royalty growth from Leqembi sales in Q4 2024